
ETON Stock Forecast & Price Target
ETON Analyst Ratings
Bulls say
Eton Pharmaceuticals Inc. is projected to experience significant revenue growth, with Khindivi associated revenues anticipated to increase from $3 million in 2025 to a peak of $28 million by 2030. The company's strategic adjustments, which include raising the probability of Khindivi's launch to 100% and adjusting its expected launch date to June 2025, demonstrate confidence in its commercial execution capabilities. Additionally, the expectation of increased market penetration, from 40% to 60%, further supports a positive outlook on the company's financial trajectory moving forward, particularly in 2025 as a potential inflection point for revenue.
Bears say
Eton Pharmaceuticals Inc. operates in a niche market with products that target rare diseases, but its reliance on a limited product portfolio may pose significant risks to future growth and profitability. The company's valuation assumptions, including an 11% discount rate and a 2% terminal growth rate, suggest a conservative outlook on its long-term earnings potential. Despite a slight upward adjustment in the price target, the financial metrics underline a fundamental concern regarding Eton’s ability to sustainably increase shareholder value in the face of market uncertainties.
This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
ETON Analyst Forecast & Price Prediction
Start investing in ETON
Order type
Buy in
Order amount
Est. shares
0 shares